Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03LTO
|
|||
| Former ID |
DNCL002464
|
|||
| Drug Name |
Tigatuzumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | ||
| Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 2 | [1] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 2 | [1] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 2 | [1] | ||
| Company |
Daiichi Sankyo
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.